


PHARMACEUTICAL 2022

Monopar Therapeutics Rank 125 of 466





Monopar Therapeutics



PHARMACEUTICAL 2022



Monopar Therapeutics Rank 125 of 466

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 135% points above the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 20,522 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 0 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 4.7 |
| Other Expenses | 0 |
| Other Liabilities | 1,581 |
| Other Net Income | 24 |
| Other Revenues | 0 |
| Property and Equipment | 0 |
| Research and Development | 6,493 |
| Selling, General and Administrative Expense | 2,634 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 20,522 |
| Liabilities | 1,581 |
| Expenses | 9,127 |
| Revenues | 0 |
| Stockholders Equity | 18,941 |
| Net Income | -9,103 |
| Comprehensive Net Income | -9,101 |
| Economic Capital Ratio | 212% |

